Literature DB >> 30140917

Cervical Cancer Screening-Moving From the Value of Evidence to the Evidence of Value.

George F Sawaya1,2,3.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30140917      PMCID: PMC6656357          DOI: 10.1001/jamainternmed.2018.4282

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  16 in total

1.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Authors:  Warner K Huh; Kevin A Ault; David Chelmow; Diane D Davey; Robert A Goulart; Francisco A R Garcia; Walter K Kinney; L Stewart Massad; Edward J Mayeaux; Debbie Saslow; Mark Schiffman; Nicolas Wentzensen; Herschel W Lawson; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2015-01-08       Impact factor: 5.482

2.  QALYs in 2018-Advantages and Concerns.

Authors:  Peter J Neumann; Joshua T Cohen
Journal:  JAMA       Date:  2018-06-26       Impact factor: 56.272

3.  The ATHENA human papillomavirus study: design, methods, and baseline results.

Authors:  Thomas C Wright; Mark H Stoler; Catherine M Behrens; Raymond Apple; Toniann Derion; Teresa L Wright
Journal:  Am J Obstet Gynecol       Date:  2011-07-22       Impact factor: 8.661

4.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Paul A Heidenreich; Paul G Barnett; Mark A Creager; Gregg C Fonarow; Raymond J Gibbons; Jonathan L Halperin; Mark A Hlatky; Alice K Jacobs; Daniel B Mark; Frederick A Masoudi; Eric D Peterson; Leslee J Shaw
Journal:  Circulation       Date:  2014-03-27       Impact factor: 29.690

5.  Practice Bulletin No. 168 Summary: Cervical Cancer Screening and Prevention.

Authors: 
Journal:  Obstet Gynecol       Date:  2016-10       Impact factor: 7.661

6.  Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Authors:  Gina Suzanne Ogilvie; Dirk van Niekerk; Mel Krajden; Laurie W Smith; Darrel Cook; Lovedeep Gondara; Kathy Ceballos; David Quinlan; Marette Lee; Ruth Elwood Martin; Laura Gentile; Stuart Peacock; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  JAMA       Date:  2018-07-03       Impact factor: 56.272

7.  Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.

Authors:  Wendy A Leyden; M Michele Manos; Ann M Geiger; Sheila Weinmann; Judy Mouchawar; Kimberly Bischoff; Marianne Ulcickas Yood; Joyce Gilbert; Stephen H Taplin
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

8.  Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  Susan J Curry; Alex H Krist; Douglas K Owens; Michael J Barry; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Martha Kubik; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

9.  Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.

Authors:  Jane J Kim; Emily A Burger; Catherine Regan; Stephen Sy
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

10.  The unintended consequences of cervical screening: distress in women undergoing cytologic surveillance.

Authors:  Linda Sharp; Seonaidh Cotton; Margaret Cruickshank; Nicola M Gray; Kirsten Harrild; Louise Smart; Leslie G Walker; Julian Little
Journal:  J Low Genit Tract Dis       Date:  2014-04       Impact factor: 1.925

View more
  1 in total

1.  Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells.

Authors:  Yanzhu Lin; Hui Zhai; Yi Ouyang; Zhiyuan Lu; Chengbiao Chu; Qianting He; Xinping Cao
Journal:  Cancer Cell Int       Date:  2019-05-14       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.